Chronic Viral Infection

Inflammation triggers unsustainable immune response

Scientists at the University of Basel discovered a fundamental new mechanism explaining the inadequate immune defense against chronic viral infection. These results may open up new avenues for vaccine development.

In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late.

A team of scientists headed by Prof. Daniel Pinschewer at the Department of Biomedicine, University of Basel, reports that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS.

Hasty immune response lasts only short-term

Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly.

The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days, but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus.

Cornerstone for new vaccines

For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable. The scientists are hopeful that the discovery of this fundamental mechanism may provide a basis to improve vaccination strategies against chronic viral diseases.


Original article
Fallet et al.: Interferon-driven deletion of antiviral B cells at the onset of chronic infection; Sci. Immunol. 1, eaah6817 (2016) | doi: 10.1126/sciimmunol.aah6817

Source: University of Basel

24.10.2016

More on the subject:
Read all latest stories

Related articles

Photo

Multiple sclerosis

Epstein-Barr virus may be leading cause of MS

A connection between the Epstein-Barr virus and multiple sclerosis has long been suspected. A new study provides ‘compelling evidence of causality’.

Photo

Potential game-changer

Telling COVID-19 apart from influenza

Researchers have developed a diagnostic for SARS-CoV-2 that is capable of differentiating between COVID-19 and the garden-variety bug with fast turnaround.

Photo

Research

Quantum sensor to detect SARS-CoV-2 faster

Scientists at have designed a quantum sensor to detect SARS-CoV-2 faster, cheaper, and more accurate than the current gold-standard technique, PCR.

Related products

Associates of Cape Cod – Fungitell STAT Assay

Identification/Susceptibility

Associates of Cape Cod – Fungitell STAT Assay

Associates of Cape Cod Europe GmbH
Hologic – Novodiag System

Automation & sample processing

Hologic – Novodiag System

Hologic, Inc.
Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Infectious Disease/Hepatitis

Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Siemens Healthineers
Subscribe to Newsletter